Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026

ASSEMBLY BIOSCIENCES, INC.

2026-Q1 EPS reported -$0.54 revenue$8,213,000

Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.
Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.
Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.
Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.
Cash runway projected into 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ASSEMBLY BIOSCIENCES, INC. reported the quarter ended March 31, 2026 results: revenue $8.2 million, net income Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share, EPS $0.54 per basic and diluted share.

Period: the quarter ended March 31, 2026
Revenue: $8.2 million
Net income: Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share
EPS: $0.54 per basic and diluted share
Result: reported results

Exact text from the filing

compared to $248.1 million as of December 31, 2025. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $8.2 million for the three months ended March 31, 2026, compared to $9.4 million for the same period in 2025. The decrease reflects the timing of activities performed and progress toward

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-211922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.